Sat Kartar Life
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · TTM
- ROCE
- 35.80%
- Debt to Equity
- 0.03
- EPS (TTM)
- —
- Book Value
- ₹43.34
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 3.05
- ROE
- 26.70%
- Dividend Yield
- 0.55%
- EBITDA
- ₹27.10 Cr
- 52W High
- ₹219.80
- 52W Low
- ₹110.30
- Volume
- 0
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Sat Kartar Life (this company) | ₹132.15 | — | ₹208 Cr | 3.05 | 0.55% | 26.70% | 35.80% | — | — |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.57% | 17.40% | 19.15% | ₹28,324 Cr | ₹3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 81/100
Category scores
- Quality
- 74
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 42
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 64
- Good
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 20
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 49
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.0%
Weaknesses
1- Working capital days have increased from 28.3 days to 60.9 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 11 | 5 | 3 |
| Oscillators | Bearish | 3 | 5 | 1 |
| Moving Averages | Strong Bearish | 8 | 0 | 2 |
Oscillators
Bearish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 45.15
- Neutral
- MACD (12,26,9)
- −5.34
- Bearish
- SMA (50)
- 141.89
- Bearish
- SMA (200)
- 153.38
- Bearish
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +32.71% |
|---|---|
| 1Y | +19.02% |
Net profit
| 3Y | +78.28% |
|---|---|
| 1Y | +70.00% |
Operating cash flow
| 3Y | — |
|---|---|
| 1Y | Outflow narrowed by ₹5 Cr |
3Y: The statements do not go back far enough for this window.
Operating margin· change in pp
| 3Y | +6.87 pp |
|---|---|
| 1Y | +4.30 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2022 | ₹52.00 Cr |
|---|---|
| Mar 2023 | ₹83.00 Cr |
| Mar 2024 | ₹128 Cr |
| Mar 2025 | ₹163 Cr |
| Mar 2026 | ₹194 Cr |
Net profit by year
| Mar 2022 | ₹1.00 Cr |
|---|---|
| Mar 2023 | ₹3.00 Cr |
| Mar 2024 | ₹6.00 Cr |
| Mar 2025 | ₹10.00 Cr |
| Mar 2026 | ₹17.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 75 | 76 | 87 | 88 | 105 |
| Expenses | 69 | 70 | 79 | 78 | 91 |
| Operating Profit | 6 | 6 | 9 | 10 | 14 |
| OPM % | 8% | 7% | 10% | 12% | 14% |
| Other Income | 0 | 0 | 1 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 |
| PBT | 5 | 5 | 8 | 11 | 13 |
| Tax % | 27% | 25% | 25% | 26% | 26% |
| Net Profit | 4 | 4 | 6 | 8 | 9 |
| EPS (₹) | 3.32 | 3.3 | 3.8 | 4.95 | 6.01 |
Profit & Loss
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 52 | 83 | 128 | 163 | 194 |
| Expenses | 49 | 78 | 118 | 149 | 169 |
| Operating Profit | 3 | 5 | 10 | 14 | 25 |
| OPM % | 5% | 6% | 8% | 9% | 13% |
| Other Income | 0 | 0 | 0 | 1 | 2 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 3 |
| PBT | 2 | 3 | 9 | 13 | 23 |
| Tax % | 7% | 27% | 27% | 25% | 26% |
| Net Profit | 1 | 3 | 6 | 10 | 17 |
| EPS (₹) | 1.24 | 2.24 | 5.63 | 6.24 | 10.96 |
| Div. Payout % | 0% | 0% | 3% | 11% | 6% |
Balance Sheet
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.7 | 0.7 | 3 | 16 | 16 |
| Reserves | 0 | 3 | 7 | 36 | 52 |
| Borrowings | 8 | 4 | 2 | 6 | 2 |
| Other Liabilities | 3 | 8 | 11 | 7 | 14 |
| Total Liabilities | 12 | 15 | 22 | 65 | 84 |
| Fixed Assets | 5 | 4 | 8 | 6 | 11 |
| CWIP | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 1 |
| Other Assets | 8 | 11 | 14 | 58 | 71 |
| Total Assets | 12 | 15 | 22 | 65 | 84 |
Cash Flow
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | — | — | 7 | −5 | 0 |
| Investing | — | — | −3 | 0 | −9 |
| Financing | — | — | −3 | 34 | −1 |
| Net Cash Flow | — | — | 2 | 28 | −9 |
| Free Cash Flow | — | — | 7 | −10 | −7 |
| CFO/EBITDA | — | — | 98 | −13 | 26 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 1 | 0 | 7 | 13 | 26 |
| Inventory Days | 31 | 25 | 23 | 185 | 258 |
| Days Payable | 165 | 226 | 237 | 170 | 293 |
| Cash Conversion Cycle | −134 | −200 | −208 | 29 | −9 |
| Working Capital Days | 1 | −14 | −7 | 31 | 61 |
| ROCE % | — | 50% | 98% | 40% | 36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sat Kartar Life insights
59 extracted metrics across FY22–FY26.
Documents
- Concall · May 2026Transcript PPT
- Concall · May 2026PPT
- Concall · Nov 2025Transcript PPT Recording
- Concall · Nov 2025Transcript
- Concall · Oct 2025PPT
- 15 Oct 2026
- 2 Oct 2026
- 1 Oct 2026
Frequently Asked Questions about Sat Kartar Life
What does Sat Kartar Life Ltd do?
Where is Sat Kartar Life Ltd (SATKARTAR) listed?
Which sector does Sat Kartar Life Ltd belong to?
What is the 52-week high and low of Sat Kartar Life Ltd?
Does Sat Kartar Life Ltd pay dividends?
What is the Return on Equity (ROE) of Sat Kartar Life Ltd?
Company Information
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SATKARTAR.md for Sat Kartar Life Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.